MetaCap

Compass Therapeutics (CMPX) vs Sutro Biopharma (STRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sutro Biopharma (STRO) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 2.4% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -94.7% for STRO. Sutro Biopharma is the larger company by market cap ($142.8 million vs $123.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMPX-85.87%STRO+2.38%
+411%+150%-111%
Nov 21, 20251 yearNov 20, 2026
CMPX-80.22%STRO-95.10%
+97%-5%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMPX versus STRO key metrics
MetricCMPXSTRO
Share price$0.6882$8.60
Market cap$123.94M$142.77M
1-day change+1.43%-1.38%
YTD return-87.18%-25.67%
1-year return-85.87%+2.38%
5-year return-78.63%-94.68%
EPS (TTM)$-0.46$-12.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$102.48M
Revenue growth (YoY)-100.00%+65.18%
Net income (latest FY)$-66.49M$-191.09M
Operating margin—-154.53%
Net margin—-186.45%
52-week high$6.88$43.85
52-week low$0.57$7.15
Distance from 52-week high-90.00%-80.39%
Analyst consensusbuystrong_buy
Avg. price target upside+664.31%+419.65%
Average volume3.88M304.90K
Shares outstanding180.09M16.60M
Employees39129
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STRO has outperformed CMPX by 88.2 percentage points over the past year.
  • Sutro Biopharma grew revenue faster in its latest fiscal year (+65.18% vs -100.00%).

About Compass Therapeutics

CMPX stock →

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

About Sutro Biopharma

STRO stock →

Sutro Biopharma, Inc. operates as an oncology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees

CMPX vs STRO FAQ

Which is bigger, Compass Therapeutics or Sutro Biopharma?

Sutro Biopharma (STRO) is larger, with a market capitalization of $142.77M compared with $123.94M for Compass Therapeutics (CMPX).

Which stock has performed better over the past year, CMPX or STRO?

STRO returned +2.38% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.

Are Compass Therapeutics and Sutro Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons